LUPIN LTD.

Lupin Ltd has announced July 17, 2026, as the record date for determining shareholder eligibility for its final dividend. The Board of Directors had previously recommended a final dividend of ₹18 per equity share (900%) for the financial year ended March 31, 2026. This dividend is subject to approval by the members at the upcoming Forty-Fourth Annual General Meeting (AGM) scheduled for August 04, 2026. If approved, the dividend will be paid within thirty days of declaration to eligible shareholders.

Lupin Ltd has announced its 44th Annual General Meeting (AGM) will be held on Tuesday, August 04, 2026, at 04:00 p.m. IST via Video Conferencing. The Board of Directors has recommended a final dividend of ₹18 per equity share for the financial year ended March 31, 2026. The record date for this dividend payment has been fixed as Friday, July 17, 2026. The dividend, if approved by shareholders at the AGM, will be paid within 30 days of declaration, subject to applicable taxes.

Global pharmaceutical major Lupin Limited has debuted on TIME and Statista's World's Most Sustainable Companies 2026 list, securing the 318th position among 750 companies. The ranking recognizes Lupin's progress in environmental stewardship, responsible business practices, governance, and social impact. The assessment considered over 20 sustainability indicators. Lupin is one of 16 Indian companies featured. The company highlighted its commitment to climate transition, renewable energy, and ESG integration, referencing its 'A' rating from CDP for Climate Change and Water Security, and a high score in S&P Global's Corporate Sustainability Assessment.

Lupin Limited announced it has received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Somerset, New Jersey. The facility received a Voluntary Action Indicated (VAI) classification following an inspection conducted from April 13-17, 2026. This positive outcome underscores Lupin's commitment to quality and compliance in its manufacturing operations. The VAI classification indicates that while some observations may have been made, they do not warrant regulatory action beyond the company's own corrective measures.

Lupin Ltd announced that its wholly owned subsidiary, Nanomi B.V., has successfully completed the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (MPPI). Additionally, MPPI has completed a buy-back of 61,118 shares, with the process for the remaining 30,559 shares ongoing. These transactions have significantly increased Nanomi's shareholding in MPPI from 56.28% to 99.89% as of July 01, 2026. This move consolidates Lupin's control over its Philippine subsidiary, potentially streamlining operations and strategic decision-making.

Lupin Limited announced that the European Medicines Agency (EMA) has approved an expansion of marketing authorization for NaMuscla. This approval includes two new dosage strengths (62 mg and 83 mg capsules) and extends the indication to cover symptomatic treatment of myotonia in children (6-11 years, weighing at least 20 kg), adolescents (12-17 years), and adults (≥18 years) with non-dystrophic myotonic disorders. NaMuscla is the only approved treatment for myotonia symptoms in NDM in Europe. Lupin is working to make these new strengths and the expanded pediatric indication available across Europe, subject to local timelines and reimbursement processes. This development is significant for patients, especially children, who have limited treatment options.

Lupin Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be closed from July 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The specific date for the board meeting to consider these results will be communicated later. This action is a standard procedure to prevent potential insider trading during sensitive financial reporting periods.

Lupin Limited has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths. The 40 mg and 80 mg strengths are bioequivalent to Astellas' Xtandi® Tablets. This approval offers alternative dosing options for healthcare providers and patients, potentially expanding Lupin's market presence in the oncology segment.

Lupin Limited has launched Azilsartan Medoxomil Tablets (40mg and 80mg) in the United States, following U.S. FDA approval. This product is bioequivalent to Edarbi® and is indicated for treating hypertension in adults. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity. Azilsartan Medoxomil Tablets had estimated annual sales of USD 53.5 million in the U.S. as of April 2026. This launch strengthens Lupin's cardiovascular portfolio in the significant U.S. market.

Lupin Limited has announced a strategic collaboration with LABORATORIOS ERN S.A. (ERN) to launch Luforbec® (beclometasone/formoterol) pMDI in Spain. This fixed-dose combination is indicated for adult asthma and COPD treatment. The partnership leverages Lupin's respiratory expertise and manufacturing capabilities with ERN's established Spanish market presence. This move signifies Lupin's commitment to expanding access to quality respiratory care in Spain, following successful launches in the UK and Germany.